Literature DB >> 16871922

Benzalkonium chloride and nasal mucociliary clearance: a randomized, placebo-controlled, crossover, double-blind trial.

José Angelo Rizzo1, Décio Medeiros, Almerinda Rego Silva, Emanuel Sarinho.   

Abstract

BACKGROUND: Benzalkonium chloride (BKC) has been considered an innocuous preservative for prescription drugs.
METHODS: We performed a double-blind, placebo-controlled, randomized, crossover, single-center trial with a 3-week washout period in 43 healthy volunteers comparing the effect of 3-week use of saline nasal spray containing BKC 0.01% to preservative-free saline t.i.d. on nasal mucociliary clearance rate. Evaluations were done at the beginning and the end of each period by gamma-scintigraphy with technetium99m-labeled strontium.
RESULTS: Nasal mucociliary clearance rate was significantly impaired by BKC with a difference of 1.23 mm x min(-1) (p < 0.01) between periods.
CONCLUSION: BKC in the concentration used in nasal preparations impaired mucociliary clearance in healthy individuals after 3 weeks of use. Presently, when preservative-free alternatives are available, BKC could be a risk without benefit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871922     DOI: 10.2500/ajr.2006.20.2867

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  3 in total

1.  Assessment of respiratory and systemic toxicity of Benzalkonium chloride following a 14-day inhalation study in rats.

Authors:  Hye-Yeon Choi; Yong-Hoon Lee; Cheol-Hong Lim; Yong-Soon Kim; In-Seop Lee; Ji-Min Jo; Ha-Young Lee; Hyo-Geun Cha; Hee Jong Woo; Dong-Seok Seo
Journal:  Part Fibre Toxicol       Date:  2020-01-28       Impact factor: 9.400

2.  Standardizing selection criteria in nasal medication studies.

Authors:  Andrei Borin; Eduardo Abib; Cleomines Izidio Araujo; Luis Lopez Martinez; Heloisio Rodrigues
Journal:  Braz J Otorhinolaryngol       Date:  2009 Nov-Dec

Review 3.  Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System.

Authors:  Tyler P Crowe; Walter H Hsu
Journal:  Pharmaceutics       Date:  2022-03-12       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.